Haemonetics Corporation Forecast, price target & analysts
Haemonetics Corporation Target price 2025 - Analyst rating & recommendation
Haemonetics Corporation Classifications & Recommendation:
Haemonetics Corporation Price Target
| Target Price | $96.80 |
| Price | $64.57 |
| Potential |
49.91%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Haemonetics Corporation 2026 .
The average Haemonetics Corporation target price is $96.80.
This is
49.91%
register free of charge
$120.00
85.84%
register free of charge
$68.00
5.31%
register free of charge
|
|
| A rating was issued by 11 analysts: 9 Analysts recommend Haemonetics Corporation to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Haemonetics Corporation stock has an average upside potential 2026 of
49.91%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.31 | 1.36 |
| 12.01% | 3.96% | |
| EBITDA Margin | 23.33% | 31.11% |
| 4.64% | 33.37% | |
| Net Margin | 8.79% | 12.18% |
| 8.73% | 38.59% |
10 Analysts have issued a sales forecast Haemonetics Corporation 2025 . The average Haemonetics Corporation sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Haemonetics Corporation EBITDA forecast 2025. The average Haemonetics Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Haemonetics Corporation Analysts have issued a net profit forecast 2025. The average Haemonetics Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Mar '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.29 | 3.30 |
| 2.23% | 44.10% | |
| P/E | 19.57 | |
| EV/Sales | 3.05 |
6 Analysts have issued a Haemonetics Corporation forecast for earnings per share. The average Haemonetics Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Haemonetics Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Haemonetics Corporation...
Current Haemonetics Corporation Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham | Locked ➜ Locked | Locked | Feb 07 2025 |
| Raymond James | Locked ➜ Locked | Locked | Feb 07 2025 |
| Barrington Research | Locked ➜ Locked | Locked | Feb 07 2025 |
| JMP Securities | Locked ➜ Locked | Locked | Feb 07 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Dec 06 2024 |
| Barrington Research | Locked ➜ Locked | Locked | Dec 04 2024 |
| Needham | Locked ➜ Locked | Locked | Dec 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
Raymond James: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
Barrington Research: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Feb 07 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Dec 06 2024 |
|
Locked
Barrington Research: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
